Extended release compositions comprising pyridostigmine
Extended release pyridostigmine dosage forms, suitable for maintaining stable plasma concentrations with reduced or minimized initial burst release/dose dumping of pyridostigmine, are provided. The dosage forms include matrix tablets, gastroretentive tablets, and pellets, the latter being suitable for dosing in capsules, tablets, and sachets, as well as for sprinkling on foodstuffs. The disclosure also provides methods for improving patient compliance by administering once-a-day extended release pyridostigmine bromide dosage forms that provide a superior controlled drug release.
1. A gastroretentive dosage form comprising an immediate release layer and an extended release component;
wherein the immediate release layer comprises between about 10 mg and about 60 mg pyridostigmine bromide; and the extended release component comprises a core and a permeable elastic membrane surrounding the core,
wherein the core comprises between about 50 mg and about 400 mg pyridostigmine bromide, hypromellose in an amount of between about 5 wt % and about 35 wt %, based on the total weight of the core, succinic acid, a carbonate salt, and a bicarbonate salt,
wherein the permeable elastic membrane comprises a plasticizer in an amount of between about 5 wt % and about 25 wt % of the membrane, and a copolymer based on ethyl acrylate, methyl methacrylate, and trimethylammonioethyl methacrylate chloride in powder form (1:2:0.2), in an amount of between about 75 wt % and about 95 wt % of the membrane, and
wherein the dosage form provides an extended release of pyridostigmine bromide for at least about 14 hours.
2. The dosage form of claim 1 , wherein the dosage form provides an in vitro release of between about 20% and about 35% of the pyridostigmine bromide within about 2 hours of dissolution in a dissolution medium comprising pH 4.5 acetate buffer with 100 mM NaCl.
3. The dosage form of claim 1 , wherein the dosage form floats in about 40 minutes or less in a dissolution medium comprising pH 4.5 acetate buffer with 100 mM NaCl.
4. The dosage form of claim 1 , wherein the dosage form, when in contact with gastric fluid, swells in about 60 minutes or less to a size that prevents its passage through pyloric sphincter.
5. The dosage form of claim 4 , wherein the dosage form maintains its integrity in a swollen state for a period of at least about 14 hours.
6. The dosage form of claim 1 , wherein the core further includes crospovidone as a wicking agent.
7. The dosage form of claim 1 , wherein the carbonate and bicarbonate salts comprise CaCO 3 and NaHCO 3 , respectively.
8. The dosage form of claim 1 , wherein the plasticizer is triethyl citrate.
9. The dosage form of claim 1 , wherein the dosage form further includes a seal coat between the permeable elastic membrane and the immediate release layer.
10. The dosage form of claim 9 , wherein the dosage form does not include a seal coat between the core and the permeable elastic membrane.
11. The dosage form of claim 9 , wherein the dosage form further includes an orifice passing through the permeable elastic membrane and the seal coat.
12. The dosage form of claim 1 , wherein the dosage form is a tablet.
13. The dosage form of claim 12 , wherein the dosage form is suitable for once daily administration and is administered as a single tablet/day.
14. The dosage form of claim 1 , wherein the hypromellose is a mixture of a low viscosity hypromellose and a high viscosity hypromellose.
15. The dosage form of claim 14 , wherein the low viscosity hypromellose has a viscosity of between about 80 mPa·s and about 120 mPa·s.
16. The dosage form of claim 14 , wherein the high viscosity hypromellose has a viscosity of between about, 2,700 mPa·s and about 5,040 mPa·s.
17. The dosage form of claim 1 , wherein the hypromellose is a high viscosity hypromellose having a viscosity of between about 2,700 mPa·s and about 5,040 mPa·s.
18. A gastroretentive dosage form comprising an immediate release layer and an extended release component;
wherein the immediate release layer comprises between about 10 mg and about 60 mg pyridostigmine bromide; and the extended release component comprises a core and a permeable elastic membrane surrounding the core,
wherein the core comprises between about 50 mg and about 400 mg pyridostigmine bromide, a high viscosity hypromellose in an amount of between about 5 wt % and about 35 wt %, based on the total weight of the core, succinic acid, a carbonate salt, and a bicarbonate salt,
wherein the high viscosity hypromellose has a viscosity of between about, 2,700 mPa·s and about 5,040 mPa·s,
wherein each of sodium bicarbonate and calcium carbonate is present in equimolar amounts with respect to succinic acid,
wherein each of sodium bicarbonate, calcium carbonate, and succinic acid is present in an amount of between about 1 wt % and about 10 wt %, based on the total weight of the core,
wherein the permeable elastic membrane comprises a plasticizer in an amount of between about 5 wt % and about 25 wt % of the membrane composition, and a copolymer based on ethyl acrylate, methyl methacrylate, and trimethylammonioethyl methacrylate chloride in powder form (1:2:0.2), in an amount of between about 75 wt % and about 95 wt % of the membrane composition, and
wherein the dosage form floats in about 40 minutes or less in pH 4.5 acetate buffer with 100 mM NaCl.
19. A gastroretentive dosage form comprising a core and a permeable elastic membrane surrounding the core,
wherein the core comprises between about 50 mg and about 400 mg pyridostigmine bromide, hypromellose in an amount of between about 5 wt % and about 35 wt %, based on the total weight of the core, succinic acid, a carbonate salt, and a bicarbonate salt,
wherein the hypromellose has a viscosity of between about, 2,700 mPa·s and about 5,040 mPa·s,
wherein each of sodium bicarbonate and calcium carbonate is present in equimolar amounts with respect to succinic acid,
wherein each of sodium bicarbonate, calcium carbonate, and succinic acid is present in an amount of between about 1 wt % and about 10 wt %, based on the total weight of the core,
wherein the permeable elastic membrane comprises a plasticizer in an amount of between about 5 wt % and about 25 wt % of the membrane composition, and a copolymer based on ethyl acrylate, methyl methacrylate, and trimethylammonioethyl methacrylate chloride in powder form (1:2:0.2), in an amount of between about 75 wt % and about 95 wt % of the membrane composition,
wherein the dosage form floats in about 40 minutes or less in pH 4.5 acetate buffer with 100 mM NaCl, and
wherein the dosage form provides an extended release of pyridostigmine bromide for at least about 14 hours.